Resi Veronica, Gaglio Alessia, Pigotskaya Yana, Caretto Amelia, Orsi Emanuela, Grancini Valeria
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Diabetes Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
Healthcare (Basel). 2024 Dec 29;13(1):38. doi: 10.3390/healthcare13010038.
The management of type 1 diabetes in pregnancy with new technologies is challenging. Sometimes the complexity of new-generation systems such as "continuous subcutaneous insulin infusion, CSII" and patient or provider preference do not allow their use, so women with type 1 diabetes in pregnancy continue to be treated with subcutaneous multiple-injection insulin therapy using pens. Smart insulin pens are new tools that allow for data collection on insulin dose and time of administration and have additional connectivity features. To retrospectively describe the use of a smart insulin pen coupled with rt-CGM (InPen system) in three pregnancies complicated by type 1 diabetes. Participants used the InPen system in pregnancy and consented to analysis of glycaemic data and pregnancy outcome. An increase in pregnancy specific time-in-range glucose was observed in the three patients related to the duration of insulin action, insulin sensitivity factors, and a pre-set target glucose range for pregnancy. No diabetic ketoacidosis or severe hypoglycaemia occurred. We describe practical considerations in three pregnant patients with type 1 diabetes where the InPen system was used with suggestive improvements in the time-in-range.
利用新技术管理妊娠期1型糖尿病具有挑战性。有时，诸如“持续皮下胰岛素输注，CSII”等新一代系统的复杂性以及患者或医护人员的偏好不允许使用这些系统，因此妊娠期1型糖尿病女性继续使用胰岛素笔进行皮下多次注射胰岛素治疗。智能胰岛素笔是一种新工具，可收集胰岛素剂量和给药时间的数据，并具有额外的连接功能。回顾性描述在三例合并1型糖尿病的妊娠中使用智能胰岛素笔与实时动态血糖监测（InPen系统）的情况。参与者在孕期使用InPen系统，并同意对血糖数据和妊娠结局进行分析。观察到三名患者与胰岛素作用持续时间、胰岛素敏感性因子以及预设的妊娠血糖目标范围相关的孕期特定血糖达标时间有所增加。未发生糖尿病酮症酸中毒或严重低血糖。我们描述了三名使用InPen系统的妊娠期1型糖尿病患者的实际情况，以及血糖达标时间有提示性改善的情况。
